Company Evolution

Founded in 2006, Patrys was listed on the Australian Stock Exchange in 2007 (symbol PAB). Headquartered in Melbourne with its research conducted in Germany and antibody manufacturing in the U.S., Patrys has grown to secure a strong first-mover advantage in developing natural human antibodies for the treatment of cancer and other deadly diseases.

Milestones

2012

• Patrys completes PAT-SM6 clinical trial in melanoma
• Multiple Myeloma trial planning underway

2011

• Former Genentech Executive Suzy Jones joins the Board
• Oversubscribed capital raising of AU$3.4M
• Patrys' CEO Dr Marie Roskrow joins the Board
• PAT-SM6 large scale manufacturing reported to scientific community
• PAT-SC1 shows significant survival benefit in gastric cancer trial
• PAT-SM6 shows promise in additional cancer indications
• PAT-SM6 antibody detected in patient tumours
• PAT-SM6shows promise in multiple myeloma
• PAT-SM6 melanoma trial progresses to final patient cohort
• PAT-SM6 inhibits metastases in melanoma cancer model
• Collaborations support PAT-SM6 clinical program
• Appointment of new CEO
• PAT-LM1 production keeps development on track
• Patrys patents allowed in major markets
• Patrys receives Company of the Year award
• Advances for PAT-SC1 gastric cancer program
• Industry interest in PAT-SM6 target grows

2010

• Groundbreaking PAT-SM6 trial initiated
• CSL collaboration signed/announced
• Lead product PAT-CM1 patent granted
• File for approval to commence first-in-human trial for PAT-SM6
• First CSL collaboration milestone reached
• Two new natural human antibodies advanced to lead pipeline
• Patrys granted key U.S. patent for lead product PAT-PM1
• Acquisition of PAT-PA1, very promising natural human antibody
• PAT-SM6 melanoma trial approved at Royal Adelaide Hospital
• $15 million funding facility announced
• Appointment of Chief Medical Officer/President

2009

• Patrys presents at scientific conferences
• Discovery/patenting of nmt55, disease target for lead PAT-LM1
• First to report manuf. platform for natural human antibodies
• Completion of preclinical development/safety testing of PAT-SM6
• Completion of preclinical development/safety testing of PAT-LM1
• $5 million rights issue at premium to market
• PAT-SM6 effective in animals at reducing colon cancer metastases
• Acquire PAT-SC1, lead product with positive human clinical data
• Patrys collaborators receives federal grant to support development of PAT-SM6

2008

• Commencement of scale-up manufacturing of lead products
• Five Patrys lead product demonstrate therapeutic potential
• Patrys completes acquisition of technologies and US$ 2 million
• Patrys-Challenge Fundraiser

2007

• Successful listing on the ASX, and raise of $25 million
• Takeda advances collaboration and completes additional investment in Patrys
• Takeda expands antibody development collaboration
• Acceptys and Seattle Biomedical Research Institute join the fight against malaria